Skip to main content

Siegfried Value Stock - Dividend - Research Selection

Siegfried Holding AG

ISIN: CH0014284498, WKN: 891169

Market price date: 26.01.2022
Market price: 727,50 CHF


Siegfried Holding AG Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 22-09-2021
Cash flow
Net operating cash flow 114.767.000
Capital Expenditures -68.762.000
Free cash flow 46.005.000
Balance sheet
Total Equity 733.184.000
Liabilities & Shareholders equity 1.242.280.000
Income statement
Net income 60.867.000
Eps (diluted) 14,556
Diluted shares outstanding 4.181.610
Net sales/revenue 845.062.000

Fundamental ratios calculated on: 26-01-2022

Ratios
Key figures 26-01-2022
Cash flow
P/C 26,51
   
P/FC 66,13
Balance sheet
ROI4,90
ROE59,02
Income statement
P/E49,98
Div. Yield0,41%
P/B4,15
P/S3,60


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSFZN.SW
Market Capitalization3.116.289.024,00 USD
CountrySwitzerland
IndicesSTOXX EUROPE 600
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen CHF
Stock Split2002-08-06,10.000000/1.000000
Internetwww.siegfried.ch


Description of the company

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling liquid dosage forms. It offers contract development and manufacturing services, including process and chemical development, analytical development, pilot manufacturing and scale up, and commercial manufacturing. The company also provides APIs and controlled substances focusing on anesthetics, pain/addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.siegfried.ch


NEWS